A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

NCT00431340 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class

Stopped Terminated due to dose limiting toxicity

Conditions

Interventions

Sponsor

Valerio Therapeutics